[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100482011":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":32,"responsibleParty":49,"collaborators":52,"id":55,"slug":30,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":30,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":30,"enrollmentInfo":63,"targetDuration":30,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":30,"overallStatus":35,"whyStopped":30,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Barbara Ann Karmanos Cancer Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"[18F]FETrp PET radiotracer","EXPERIMENTAL","All participants will receive the tracer to evaluate the uptake of \\[18F\\]FETrp PET\u002FCT on intra- and extracranial cancers.",[13],"Drug: 1-(2-[18F]FLUOROETHYL)-L-Tryptophan",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","1-(2-[18F]FLUOROETHYL)-L-Tryptophan","Radioactive tracer 1-(2-\\[18F\\]FLUOROETHYL)-L-Tryptophan 0.14mCi\u002Fkg\u002F5MBq\u002Fkg injection given one time prior to PET Scan.",[9],[9],[22],{"name":23,"affiliation":5,"role":24},"Csaba Juhasz, M.D.,Ph.D","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Csaba Juhasz, M.D., Ph.D","CONTACT","313-966-5136",null,"csaba.juhasz@wayne.edu",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Karmanos Cancer Institute","RECRUITING","Detroit","Michigan","48201","United States",{"type":41,"coordinates":42},"Point",[43,44],-83.04575,42.33143,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":29,"phoneExt":30,"email":31},"Csaba Juhasz, MD, PhD",{"type":24,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Csaba Juhasz","Principal Investigator",[53],{"name":54,"class":6},"Washington University School of Medicine","100482011",false,"NCT05556473","F-Tryptophan PET\u002FCT in Human Cancers","A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET\u002FCT Imaging In Human Cancers","Inclusion Criteria:\n\n* Age ≥18 years.\n* Targeted lesion (tumor) is at least 1 cm in diameter as shown by clinical imaging.\n* Patient is able to lie in the PET\u002FCT scanner for at least 70 minutes while undergoing scanning.\n* Women of childbearing potential must not be pregnant or breastfeeding.\n* Recent anatomic imaging with visible disease (tumor) for comparison with the PET\u002FCT. .\n* Physical exam within 28 days of PET imaging, CBC and Multiphasic (including electrolytes, BUN, creatinine, total bilirubin, AST and ALT) within 14 days.\n* Patients must sign an informed consent indicating that they are aware of the investigational nature of this study.\n\nInclusion Criteria Specific for Intracranial Tumors\n\n\\- Clinical and MRI diagnosis of an intracranial lesion suspicious for a brain tumor, including gliomas or metastatic brain tumors; primary, residual, or recurrent brain tumors (judged by clinical imaging) will qualify.\n\nInclusion Criteria Specific for Extracranial Neuroendocrine Tumors:\n\n* Histopathologically confirmed, well-differentiated metastatic neuroendocrine tumor.\n* ECOG performance status of 2 or better.\n* Patients receiving stable-dose somatostatin analogs (SSAs, long-acting release \\[LAR\\], depot) for \\>3 months before enrollment may be enrolled on the study, but such treatment is not required.\n\nInclusion Criteria specific for Extracranial Primary Breast tumors:\n\n* Clinical and radiological diagnosis of a breast cancer\n* ECOG performance status of 2 or better.\n\nInclusion Criteria specific for Rectal tumors:\n\n* Histologically confirmed colorectal cancer, which is located in the rectum.\n* ECOG performance status of 2 or better.\n\nExclusion Criteria:\n\n* Patients who are pregnant or lactating are excluded.\n\nExclusion Criteria Specific for Intracranial Tumors:\n\n* Severe increased intracranial pressure, status epilepticus, or other symptoms requiring emergency or urgent intervention.\n* Tumor surgery or radiation within 1 month prior to the PET scan\n\nExclusion Criteria Specific for Extracranial Neuroendocrine Tumors:\n\n* Tumor-directed therapy within 3 months to the area of planned imaging.\n* Ongoing treatment with a targeted agent (e.g., sunitinib or everolimus) or receiving cytotoxic chemotherapy (e.g., capecitabine or temozolomide).\n* Use of telotristat ethyl (a tryptophan-hydroxylase inhibitor) within one month.\n\nExclusion Criteria for Extracranial Primary Breast tumors:\n\n-Recent (within 1 month) tumor resection or radio-chemotherapy (acute\u002Fsubacute post-treatment inflammatory changes may cause false positive increases on PET).\n\nExclusion Criteria for Rectal tumors:\n\n-Active inflammatory bowel disease (Crohn's or Ulcerative colitis) involving the rectum.","ALL","18 Years",{"count":64,"type":65},24,"ESTIMATED","INTERVENTIONAL",[68],"PHASE1","Imaging procedures such as 1-(2-\\[18F\\]FLUOROETHYL)-L-Tryptophan PET\u002FCT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.",[71,72,73,74,75],"Intracranial Glioma","Metastatic Brain Tumor","Breast Cancer","Neuroendocrine Tumors","Rectal Cancer","2026-01-21",{"date":78,"type":79},"2026-01-23","ACTUAL",{"date":81,"type":79},"2022-09-29",{"date":83,"type":65},"2027-12-31",{"name":5,"class":6},1]